Barclays on CVS Caremark: With No Upfront Payment, CVS's Deal with Aetna Looks Superior to ESRX/WLP Deal
Tweet Send to a Friend
Barclays reiterates an 'Overweight' rating on CVS Corp (NYSE: CVS), price target $40.
Barclays analyst says, "The PBM outsourcing contract ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "The PBM outsourcing contract ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
